Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
In several multi-center longitudinal studies involving hemodialysis cohorts, the administration of IV Levocarnitine demonstrated a significant reduction in the ESA Resistance Index. Numerical data from recent trials indicates: Anemia Management: Patients receiving IV Levocarnitine showed an average 15% to 25% reduction in the required dose of Erythropoietin (EPO) to maintain target hemoglobin levels
Sodium Free
Nutritional Supplements/ Nutraceutical Supplements 4.3.3
Cells were treated with Erastin (Selleck, S7242), IMP-366 (AOBIOUS, AOB6657), DFO (Sigma, D9533), Fer-1 (Selleck, S7243), Lip-1 (Selleck, S7699), iFSP1 (Cayman Chemical, 29483), Z-VAD-FMK (Selleck, S7023), MCC950 (Selleck, S8930), Nec-1 (Selleck, S8037), and IVM (APExBIO, A2813)
Presented for research literature review only Zhang L et al
